(BF-B) Brown-Forman - Overview
Stock: Spirits, Whiskey, Vodka, Tequila, Rum
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.99% |
| Yield on Cost 5y | 1.32% |
| Yield CAGR 5y | -14.78% |
| Payout Consistency | 88.7% |
| Payout Ratio | 53.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 37.0% |
| Relative Tail Risk | -4.00% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.01 |
| Alpha | -12.90 |
| Character TTM | |
|---|---|
| Beta | 0.553 |
| Beta Downside | 0.280 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.30% |
| CAGR/Max DD | -0.35 |
Description: BF-B Brown-Forman January 02, 2026
Brown-Forman Corp. (NYSE: BF-B) is a global producer and marketer of distilled spirits and wines, operating a portfolio that includes flagship brands such as Jack Daniel’s, Woodford Reserve, Old Forester, and Herradura, as well as a range of premium whiskies, vodkas, gins, and ready-to-drink cocktails. The firm also monetizes secondary assets through used-barrel sales, bulk whiskey and wine transactions, and contract bottling services, serving retail, wholesale, and governmental channels across North America, Europe, Asia-Pacific, and Latin America.
Key performance indicators from FY 2024 show net sales of roughly $4.6 billion, an operating margin of 28 %, and a free-cash-flow conversion of about 70 % of earnings, reflecting strong pricing power in the premium-spirits segment. The business’s exposure to discretionary consumer spending makes it sensitive to macro-economic variables such as U.S. consumer confidence and real disposable income, while the ongoing “premiumization” trend-where consumers shift toward higher-priced, higher-quality spirits-has been a primary growth driver. Additionally, the company’s relatively low leverage (debt-to-equity ~0.4×) provides flexibility to fund acquisitions or share-repurchase programs.
For a deeper quantitative assessment, you may find ValueRay’s platform useful for comparing BF-B’s valuation and risk metrics against its peers.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 810.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 1.92 > 1.0 |
| NWC/Revenue: 71.78% < 20% (prev 64.80%; Δ 6.98% < -1%) |
| CFO/TA 0.09 > 3% & CFO 761.0m > Net Income 810.0m |
| Net Debt (2.33b) to EBITDA (1.21b): 1.92 < 3 |
| Current Ratio: 2.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (472.6m) vs 12m ago -0.10% < -2% |
| Gross Margin: 59.17% > 18% (prev 0.59%; Δ 5858 % > 0.5%) |
| Asset Turnover: 47.05% > 50% (prev 48.96%; Δ -1.91% > 0%) |
| Interest Coverage Ratio: 10.30 > 6 (EBITDA TTM 1.21b / Interest Expense TTM 109.0m) |
Altman Z'' 6.29
| A: 0.34 (Total Current Assets 4.21b - Total Current Liabilities 1.42b) / Total Assets 8.22b |
| B: 0.59 (Retained Earnings 4.89b / Total Assets 8.22b) |
| C: 0.14 (EBIT TTM 1.12b / Avg Total Assets 8.28b) |
| D: 1.15 (Book Value of Equity 4.72b / Total Liabilities 4.09b) |
| Altman-Z'' Score: 6.29 = AAA |
Beneish M -2.96
| DSRI: 1.14 (Receivables 1.04b/954.0m, Revenue 3.89b/4.08b) |
| GMI: 1.00 (GM 59.17% / 59.21%) |
| AQI: 0.96 (AQ_t 0.35 / AQ_t-1 0.37) |
| SGI: 0.95 (Revenue 3.89b / 4.08b) |
| TATA: 0.01 (NI 810.0m - CFO 761.0m) / TA 8.22b) |
| Beneish M-Score: -2.96 (Cap -4..+1) = A |
What is the price of BF-B shares?
Over the past week, the price has changed by +7.60%, over one month by +12.84%, over three months by +11.88% and over the past year by -2.91%.
Is BF-B a buy, sell or hold?
- StrongBuy: 2
- Buy: 3
- Hold: 10
- Sell: 3
- StrongSell: 2
What are the forecasts/targets for the BF-B price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.3 | 2.8% |
| Analysts Target Price | 30.3 | 2.8% |
| ValueRay Target Price | 25.4 | -13.7% |
BF-B Fundamental Data Overview February 04, 2026
P/E Forward = 16.5837
P/S = 3.2302
P/B = 3.0668
P/EG = 4.9369
Revenue TTM = 3.89b USD
EBIT TTM = 1.12b USD
EBITDA TTM = 1.21b USD
Long Term Debt = 2.07b USD (from longTermDebt, last quarter)
Short Term Debt = 575.0m USD (from shortTermDebt, last quarter)
Debt = 2.65b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.33b USD (from netDebt column, last quarter)
Enterprise Value = 14.89b USD (12.56b + Debt 2.65b - CCE 319.0m)
Interest Coverage Ratio = 10.30 (Ebit TTM 1.12b / Interest Expense TTM 109.0m)
EV/FCF = 24.41x (Enterprise Value 14.89b / FCF TTM 610.0m)
FCF Yield = 4.10% (FCF TTM 610.0m / Enterprise Value 14.89b)
FCF Margin = 15.67% (FCF TTM 610.0m / Revenue TTM 3.89b)
Net Margin = 20.80% (Net Income TTM 810.0m / Revenue TTM 3.89b)
Gross Margin = 59.17% ((Revenue TTM 3.89b - Cost of Revenue TTM 1.59b) / Revenue TTM)
Gross Margin QoQ = 59.56% (prev 59.74%)
Tobins Q-Ratio = 1.81 (Enterprise Value 14.89b / Total Assets 8.22b)
Interest Expense / Debt = 0.98% (Interest Expense 26.0m / Debt 2.65b)
Taxrate = 19.71% (55.0m / 279.0m)
NOPAT = 901.6m (EBIT 1.12b * (1 - 19.71%))
Current Ratio = 2.97 (Total Current Assets 4.21b / Total Current Liabilities 1.42b)
Debt / Equity = 0.64 (Debt 2.65b / totalStockholderEquity, last quarter 4.13b)
Debt / EBITDA = 1.92 (Net Debt 2.33b / EBITDA 1.21b)
Debt / FCF = 3.82 (Net Debt 2.33b / FCF TTM 610.0m)
Total Stockholder Equity = 3.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.79% (Net Income 810.0m / Total Assets 8.22b)
RoE = 20.33% (Net Income TTM 810.0m / Total Stockholder Equity 3.98b)
RoCE = 18.54% (EBIT 1.12b / Capital Employed (Equity 3.98b + L.T.Debt 2.07b))
RoIC = 13.42% (NOPAT 901.6m / Invested Capital 6.72b)
WACC = 6.70% (E(12.56b)/V(15.21b) * Re(7.95%) + D(2.65b)/V(15.21b) * Rd(0.98%) * (1-Tc(0.20)))
Discount Rate = 7.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.78%
[DCF Debug] Terminal Value 82.84% ; FCFF base≈549.2m ; Y1≈539.3m ; Y5≈550.5m
Fair Price DCF = 36.21 (EV 13.00b - Net Debt 2.33b = Equity 10.67b / Shares 294.6m; r=6.70% [WACC]; 5y FCF grow -2.73% → 2.90% )
EPS Correlation: 5.02 | EPS CAGR: -3.63% | SUE: 0.0 | # QB: 0
Revenue Correlation: -37.44 | Revenue CAGR: 0.10% | SUE: 0.56 | # QB: 0
EPS current Year (2026-04-30): EPS=1.64 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-10.6% | Growth Revenue=-3.2%
EPS next Year (2027-04-30): EPS=1.73 | Chg30d=-0.003 | Revisions Net=-1 | Growth EPS=+5.2% | Growth Revenue=+1.7%